Compare HRL & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRL | NBIX |
|---|---|---|
| Founded | 1891 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 13.2B |
| IPO Year | 1994 | 1996 |
| Metric | HRL | NBIX |
|---|---|---|
| Price | $24.06 | $158.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 22 |
| Target Price | $26.50 | ★ $180.91 |
| AVG Volume (30 Days) | ★ 4.6M | 984.1K |
| Earning Date | 05-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.61% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | 0.62 | ★ 1.91 |
| Revenue | ★ $12,106,160,000.00 | $161,626,000.00 |
| Revenue This Year | $2.66 | $24.73 |
| Revenue Next Year | $1.62 | $13.14 |
| P/E Ratio | ★ $39.02 | $83.16 |
| Revenue Growth | 1.55 | ★ 977.51 |
| 52 Week Low | $19.72 | $122.14 |
| 52 Week High | $31.11 | $169.57 |
| Indicator | HRL | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 64.50 | 51.40 |
| Support Level | $23.23 | $153.30 |
| Resistance Level | $24.62 | $160.08 |
| Average True Range (ATR) | 0.49 | 5.41 |
| MACD | 0.05 | -1.42 |
| Stochastic Oscillator | 59.05 | 21.24 |
Historically meat-focused, Hormel Foods broadened its lineup to include other protein offerings and became a branded food company. The firm sells its wares through multiple channels, including US retail (61.6% of fiscal 2025 sales), US foodservice (32.6%), and international (5.9%). By product, 73% of fiscal 2025 sales were from perishable food and 27% from shelf-stable. Major brands include Hormel, Spam, Jennie-O, Columbus, Applegate, Planters, and Skippy. Many of these hold the number one or two market share in their respective categories.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.